The Melanocortin and Endorphin Neuropeptides in Patients with Restless Legs Syndrome

Abstract

ObjectiveBased upon similarities between the urge to move and sensory discomfort of restless legs syndrome (RLS) and properties of melanocortin hormones, including their incitement of movement and hyperalgesia, we assessed plasma and cerebrospinal fluid (CSF) α‐melanocyte‐stimulating hormone (α‐MSH) and β‐endorphin in RLS patients and controls.MethodsForty‐two untreated moderate‐to‐severe RLS patients and 44 matched controls underwent venipuncture at 19:00, 20:30, and 22:00; 37 RLS and 36 controls had lumbar puncture at 21:30. CSF and plasma were analyzed for pro‐opiomelanocortin (POMC), adrenocorticotropin hormone (ACTH), α‐MSH, β‐MSH, and β‐endorphin by immunoassay. RLS severity was assessed by International RLS Study Group Severity Scale.ResultsRLS participants were 52.7 ± 12.0 years old, 61.9% were women, 21.4% had painful RLS, and RLS severity was 24.8 ± 9.0. Controls had similar age and sex. Plasma ACTH, α‐MSH, and β‐endorphin were similar between groups. Plasma POMC was significantly greater in RLS than controls (17.0 ± 11.5 vs 12.7 ± 6.1fmol/ml, p = 0.048). CSF ACTH was similar between groups. CSF β‐MSH was significantly higher in painful than nonpainful RLS or controls (48.2 ± 24.8 vs 32.1 ± 14.8 vs 32.6 ± 15.2pg/ml, analysis of variance [ANOVA] p = 0.03). CSF α‐MSH was higher in RLS than controls (34.2 ± 40.9 vs 20.3 ± 11.0pg/ml, p = 0.062). CSF β‐EDP was lowest in painful RLS, intermediate in nonpainful RLS, and highest in controls (8.0 ± 3.4 vs 10.8 ± 3.1 vs 12.3 ± 5.0pg/ml, ANOVA p = 0.049). The ratio of the sum of CSF α‐ and β‐MSH to CSF β‐endorphin was highest, intermediate, and lowest in painful RLS, nonpainful RLS, and controls (p = 0.007).InterpretationCSF β‐MSH is increased and CSF β‐endorphin decreased in RLS patients with painful symptoms. ANN NEUROL 2024